48 results on '"Palma, Julia"'
Search Results
2. The TeLeo Program: Tele‐education in pediatric oncology as a tool to support training programs in Latin America.
- Author
-
Sampor, Claudia, Alonso, Rocio, Durañona, Mariana, Gorostegui, Maite, Antillón‐Klussmann, Federico, Lopes, Luiz Fernando, Cappellano, Andrea M., Gonzalez‐Ramella, Oscar, Lobos, Pablo, Palma, Julia, Grynszpancholc, Edith, Vasquez, Liliana, Morales La Madrid, Andrés, Moreira, Daniel C., Cruz, Ofelia, and Chantada, Guillermo
- Published
- 2024
- Full Text
- View/download PDF
3. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
- Author
-
Ribelles, A Juan, Balduzzi, Adriana, Elhaddad, Alaa, Casanovas, Alejandra, Garcia Velazquez, Alejandra, Laptsevich, Aliaksandra, Chang, Alicia, F. Sampaio, Alessandra Lamenha, González Prieto, Almudena, Lassaletta, Alvaro, Suarez M, Amaranto, Alcasabas, Ana Patricia, Colita, Anca, Morales La Madrid, Andres, Samudio, Angélica, Tondo, Annalisa, Colombini, Antonella, Kattamis, Antonis, Lopez Facundo, N Araceli, Bhattacharyya, Arpita, Alimi, Aurélia, Phulpin, Aurélie, Vakrmanova, Barbora, Aksoy, Basak A, Brethon, Benoit, Kobuin, Jator Brian, Nolasco Monteiro, Carla, Paillard, Catherine, Vezina, Catherine, Ceyhun, Bozkurt, Hentea, Cristiana, Meazza, Cristina, Ortiz-Morales, Daniel, Solorzano, Roque Daniel, Arce Cabrera, Daniela, Zama, Daniele, Ghosh, Debjani, Ramírez-Rivera, Diana, Calle Jara, Doris A, Janic, Dragana, Rey Helo, Elianneth, Gouache, Elodie, Guerrero Quiroz, Enmanuel, Lopez, Enrique, Thebault, Eric, Maradiegue, Essy, de Berranger, Eva, Ebeid, Fatma S E, Galaverna, Federica, Antillon-Klussmann, Federico, Espinoza Chacur, Felipe, Negro, Fernando Daniel, Carraro, Francesca, Compagno, Francesca, Barriga, Francisco, Tamayo Pedraza, Gabriela, Sanchez Fernandez, Gissela, Naidu, Gita, Tokuc, Gülnur, Alias, Hamidah, B Segocio, Hannah Grace, Boudiaf, Houda, Asetre Luna, Imelda, Maia, Iris, Astigarraga, Itziar, Maza, Ivan, Montoya Vásquez, Jacqueline E, Jazbec, Janez, Lazic, Jelena, Beck Dean, Jeniffer, Rouger-Gaudichon, Jeremie, Contreras González, Johanny Carolina, Huerta Aragonés, Jorge, Fuster, José L, Quintana, Juan, Palma, Julia, Svojgr, Karel, Quintero, Karina, Malic Tudor, Karolina, Georgantzi, Kleopatra, P Schultz, Kris Ann, Ureña Horno, Laura, Fraquelli, Lidia, Meneghello, Linda, Shalaby, Lobna, Macias Mora, Lola L, A Renner, Lorna, Nunes Silva, Luciana, Sisinni, Luisa, Hammad, Mahmoud, Fernández Sanmartín, M, Zubieta A, C Marcela, Drozdowski, María Constanza, Kourti, Maria, Palladino, Marcela María, Miranda Madrazo, Maria R, Poiree, Marilyne, Popova, Marina, Melgar, Mario, Baragaño, Marta, Avilés-Robles, Martha J, Provenzi, Massimo, Mendes Lins, Mecneide, Fatih Orhan, Mehmet, Villarroel, Milena, Jerónimo, Mónica, Varas Palma, Mónica, Rafie Raza, Muhammad, M Justin, Mulindwa, Shaheen, Najma, Domínguez-Pinilla, Nerea, Whipple, Nicholas S, André, Nicolas, Hrusak, Ondrej, Velasco Puyó, Pablo, Zacasa Vargas, Pamela, Olate Mellado, Paola, Yola Gassant, Pascale, Diaz Romero, Paulina, De Santis, Raffaella, Kebudi, Rejin, Boranbayeva, Riza, Vasquez, Roberto, Segura, Romel A., Rosado, Roy Enrique, Gómez, Sandra, Raimbault, Sandra, Gunasekera, Sanjeeva, Makkeyah, Sara M, Buyukkapu Bay, Sema, M Gómez, Sergio, Bouttefroy, Séverine, Islam, Shahnoor, Abouelnaga, Sherif, Torres, Silvio Fabio, Cesaro, Simone, Nunes, Sofia, Rouxinol, Soraia, Bhaumik, Sucharita, Saliyeva, Symbat, Inostroza, Tamara, Velasquez, Thelma, Hnin, Tint Myo, Norén-Nyström, Ulrika, Baretta, Valentina, Jimenez-Antolinez, Yajaira Valentine, Pérez Alonso, Vanesa, Ayer Miller, Vanessa, Gandemer, Virginie, Lotero, Viviana, Mishkova, Volha, Gómez-García, Wendy, Margaryan, Yeva, Syed, Yumna, Mukkada, Sheena, Bhakta, Nickhill, Chantada, Guillermo L, Chen, Yichen, Vedaraju, Yuvanesh, Faughnan, Lane, Homsi, Maysam R, Muniz-Talavera, Hilmarie, Ranadive, Radhikesh, Metzger, Monika, Friedrich, Paola, Agulnik, Asya, Jeha, Sima, Lam, Catherine, Dalvi, Rashmi, Hessissen, Laila, Moreira, Daniel C, Santana, Victor M, Sullivan, Michael, Bouffet, Eric, Caniza, Miguela A, Devidas, Meenakshi, Pritchard-Jones, Kathy, and Rodriguez-Galindo, Carlos
- Published
- 2021
- Full Text
- View/download PDF
4. International Society of Paediatric Oncology (SIOP) Global Mapping Program: Analysis of healthcare centers in countries of the Latin American Society of Pediatric Oncology (SLAOP).
- Author
-
Gorostegui‐Obanos, Maite, Chantada, Luisa, Filho, Nevicolino Pereira Carvalho, Gonzalez‐Ramella, Oscar, Serrano B, María J., Valencia, Diana, Sampor, Claudia, Macedo, Carla, Ramirez, Oscar, Sardinas, Susan, Lezcano, Eva, Calderón, Patricia, Gamboa, Yessika, Fu, Ligia, Gómez, Wendy, Schelotto, Magdalena, Ugaz, Cecilia, Lobos, Pablo, Moreno, Katiuska, and Palma, Julia
- Published
- 2024
- Full Text
- View/download PDF
5. 5 years DKMS Chile: approach, results and impact of the first unrelated stem cell donor center in Chile
- Author
-
Barriga, Francisco, primary, Solloch, Ute V., additional, Giani, Anette, additional, Palma, Julia, additional, Wietstruck, Angélica, additional, Sarmiento, Mauricio, additional, Carvallo, Cristian, additional, Mosso, Claudio, additional, Ramirez, Pablo, additional, Sanchez, Matias, additional, Rojas, Nicolas, additional, Alfaro, Jorge, additional, Saldaña, Sebastian, additional, Ende, Karen, additional, Flaig, Denis, additional, Pattillo, Ignacia, additional, and Schmidt, Alexander H., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Hematopoietic Stem Cell Transplant
- Author
-
Palma, Julia, Sotomayor, Cristián, Stefan, Daniela Cristina, editor, and Rodriguez-Galindo, Carlos, editor
- Published
- 2014
- Full Text
- View/download PDF
7. Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study
- Author
-
Dalle, Jean-Hugues, primary, Bader, Peter, additional, Yesilipek, Akif, additional, Locatelli, Franco, additional, Palma, Julia, additional, Wachowiak, Jacek, additional, Pichler, Herbert, additional, Ifversen, Marianne, additional, Kriván, Gergely, additional, Buechner, Jochen, additional, Díaz-de-Heredia, Cristina, additional, Bierings, Marc, additional, Staciuk, Raquel, additional, Gungor, Tayfun, additional, Toporski, Jacek, additional, Balduzzi, Adriana, additional, Poetschger, Ulrike, additional, Peters, Christina, additional, and Sedlacek, Petr, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Slow Tourism : el binomi turisme de proximitat i industrial
- Author
-
El Briyak Ereddam, Hafsa, Palma, Julia, Vicente i Campos, Oriol, Sanchez, Anna, El Briyak Ereddam, Hafsa, Palma, Julia, Vicente i Campos, Oriol, and Sanchez, Anna
- Abstract
La crisi sorgida per la Pandèmia de la Covid-19, ha provocat canvis socioeconòmics importants, tant en la forma de treballar, com en la formació, en la mobilitat, el consum, el lleure... I el sector turístic no n'és excepció. El "turisme de proximitat" apareix com a alternativa per revitalitzar el sector i fa referència a la pràctica de viatjar i redescobrir espais a prop de l'entorn quotidià. Un fet que propicia des de descobertes de l'entorn natural, del patrimoni cultural, de petits productors i alhora, també, del patrimoni industrial.
- Published
- 2022
9. Impact of COVID‐19 in pediatric oncology care in Latin America during the first year of the pandemic
- Author
-
Villanueva, Gabriela, primary, Sampor, Claudia, additional, Palma, Julia, additional, Villarroel, Milena, additional, Valencia, Diana, additional, Lombardi, Mercedes García, additional, Garcia, Wendy Gomez, additional, Caceres, Eva Lezcano, additional, Sobrero, Victoria, additional, Garcia, Lilia, additional, Cabrera, Victor, additional, Maza, Ivan, additional, Velasquez, Thelma, additional, Ugaz, Cecilia, additional, Vasquez, Jacqueline Montoya, additional, Coronado, Rosdali Diaz, additional, Gonzalez, Natalia, additional, Aguiar, Simone, additional, Dabezies, Agustin, additional, Moreno, Florencia, additional, Sardinas, Susan, additional, Gamboa, Yessika, additional, Maradiegue, Essy, additional, Fu, Ligia, additional, Gassant, Pascale, additional, Moreno, Katiuska, additional, Gonzales, Oscar, additional, Schelotto, Magdalena, additional, Luna‐Fineman, Sandra, additional, Antoneli, Celia Gianotti, additional, Fuentes‐Alabi, Soad, additional, Luciani, Silvana, additional, Cappellano, Andrea, additional, Chantada, Guillermo, additional, and Vasquez, Liliana, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Sharing Best Practice: Establishing a National Vietnamese Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy Consortium
- Author
-
Nguyen, Sang M., primary, Huynh, Phu D.V., additional, Abramovitz, Linda, additional, Agrawal, Anu, additional, Assanasen, Chatchawin, additional, Blair, Sally, additional, Chu, Minh H., additional, Faulkner, Lawrence, additional, Hoang, Tram T.A., additional, Ho, Hang T.K., additional, Horn, Biljana, additional, Huynh, Chau T.B., additional, Le, Anh H., additional, Le, Phuong B., additional, Le, Son T., additional, Noonan, Nancy, additional, Nguyen, Dinh V., additional, Nguyen, Hang T.T., additional, Nguyen, Hoa T.K., additional, Nguyen, Nam H., additional, Nguyen, Nhai T., additional, Nguyen, Tho T., additional, Oh, Jess, additional, Palma, Julia, additional, Phan, Trang T.T., additional, Pham, Anh T.N., additional, Pham, Tuan M., additional, Rees, Hannah, additional, Tan, Poh-Lin, additional, Tran, My, additional, Vo, Binh T.T., additional, Watanabe, Kazuyo, additional, Yi, Hyeon Gyu, additional, Bui, Lan N., additional, and Hermiston, Michelle, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Evaluación de la dosificación de voriconazol intravenoso tres veces al día vs dos veces al día para el tratamiento de aspergilosis invasora en niños inmunocomprometidos: monitorización terapéutica y seguridad
- Author
-
Barraza, Marlon, primary, Torres, Juan P., additional, Coria, Paulina, additional, Miranda, René, additional, Palma, Julia, additional, García, Patricio, additional, Azócar, Manuel, additional, Santolaya, M. Elena, additional, and Morales, Jorge, additional
- Published
- 2022
- Full Text
- View/download PDF
12. T-Cell-Replete Versus ex vivo T-Cell-Depleted Haploidentical Haematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukaemia and Other Haematological Malignancies
- Author
-
Kleinschmidt, Katharina, primary, Lv, Meng, additional, Yanir, Asaf, additional, Palma, Julia, additional, Lang, Peter, additional, and Eyrich, Matthias, additional
- Published
- 2021
- Full Text
- View/download PDF
13. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
- Author
-
Mukkada, Sheena, primary, Bhakta, Nickhill, additional, Chantada, Guillermo L, additional, Chen, Yichen, additional, Vedaraju, Yuvanesh, additional, Faughnan, Lane, additional, Homsi, Maysam R, additional, Muniz-Talavera, Hilmarie, additional, Ranadive, Radhikesh, additional, Metzger, Monika, additional, Friedrich, Paola, additional, Agulnik, Asya, additional, Jeha, Sima, additional, Lam, Catherine, additional, Dalvi, Rashmi, additional, Hessissen, Laila, additional, Moreira, Daniel C, additional, Santana, Victor M, additional, Sullivan, Michael, additional, Bouffet, Eric, additional, Caniza, Miguela A, additional, Devidas, Meenakshi, additional, Pritchard-Jones, Kathy, additional, Rodriguez-Galindo, Carlos, additional, Ribelles, A Juan, additional, Balduzzi, Adriana, additional, Elhaddad, Alaa, additional, Casanovas, Alejandra, additional, Garcia Velazquez, Alejandra, additional, Laptsevich, Aliaksandra, additional, Chang, Alicia, additional, F. Sampaio, Alessandra Lamenha, additional, González Prieto, Almudena, additional, Lassaletta, Alvaro, additional, Suarez M, Amaranto, additional, Alcasabas, Ana Patricia, additional, Colita, Anca, additional, Morales La Madrid, Andres, additional, Samudio, Angélica, additional, Tondo, Annalisa, additional, Colombini, Antonella, additional, Kattamis, Antonis, additional, Lopez Facundo, N Araceli, additional, Bhattacharyya, Arpita, additional, Alimi, Aurélia, additional, Phulpin, Aurélie, additional, Vakrmanova, Barbora, additional, Aksoy, Basak A, additional, Brethon, Benoit, additional, Kobuin, Jator Brian, additional, Nolasco Monteiro, Carla, additional, Paillard, Catherine, additional, Vezina, Catherine, additional, Ceyhun, Bozkurt, additional, Hentea, Cristiana, additional, Meazza, Cristina, additional, Ortiz-Morales, Daniel, additional, Solorzano, Roque Daniel, additional, Arce Cabrera, Daniela, additional, Zama, Daniele, additional, Ghosh, Debjani, additional, Ramírez-Rivera, Diana, additional, Calle Jara, Doris A, additional, Janic, Dragana, additional, Rey Helo, Elianneth, additional, Gouache, Elodie, additional, Guerrero Quiroz, Enmanuel, additional, Lopez, Enrique, additional, Thebault, Eric, additional, Maradiegue, Essy, additional, de Berranger, Eva, additional, Ebeid, Fatma S E, additional, Galaverna, Federica, additional, Antillon-Klussmann, Federico, additional, Espinoza Chacur, Felipe, additional, Negro, Fernando Daniel, additional, Carraro, Francesca, additional, Compagno, Francesca, additional, Barriga, Francisco, additional, Tamayo Pedraza, Gabriela, additional, Sanchez Fernandez, Gissela, additional, Naidu, Gita, additional, Tokuc, Gülnur, additional, Alias, Hamidah, additional, B Segocio, Hannah Grace, additional, Boudiaf, Houda, additional, Asetre Luna, Imelda, additional, Maia, Iris, additional, Astigarraga, Itziar, additional, Maza, Ivan, additional, Montoya Vásquez, Jacqueline E, additional, Jazbec, Janez, additional, Lazic, Jelena, additional, Beck Dean, Jeniffer, additional, Rouger-Gaudichon, Jeremie, additional, Contreras González, Johanny Carolina, additional, Huerta Aragonés, Jorge, additional, Fuster, José L, additional, Quintana, Juan, additional, Palma, Julia, additional, Svojgr, Karel, additional, Quintero, Karina, additional, Malic Tudor, Karolina, additional, Georgantzi, Kleopatra, additional, P Schultz, Kris Ann, additional, Ureña Horno, Laura, additional, Fraquelli, Lidia, additional, Meneghello, Linda, additional, Shalaby, Lobna, additional, Macias Mora, Lola L, additional, A Renner, Lorna, additional, Nunes Silva, Luciana, additional, Sisinni, Luisa, additional, Hammad, Mahmoud, additional, Fernández Sanmartín, M, additional, Zubieta A, C Marcela, additional, Drozdowski, María Constanza, additional, Kourti, Maria, additional, Palladino, Marcela María, additional, Miranda Madrazo, Maria R, additional, Poiree, Marilyne, additional, Popova, Marina, additional, Melgar, Mario, additional, Baragaño, Marta, additional, Avilés-Robles, Martha J, additional, Provenzi, Massimo, additional, Mendes Lins, Mecneide, additional, Fatih Orhan, Mehmet, additional, Villarroel, Milena, additional, Jerónimo, Mónica, additional, Varas Palma, Mónica, additional, Rafie Raza, Muhammad, additional, M Justin, Mulindwa, additional, Shaheen, Najma, additional, Domínguez-Pinilla, Nerea, additional, Whipple, Nicholas S, additional, André, Nicolas, additional, Hrusak, Ondrej, additional, Velasco Puyó, Pablo, additional, Zacasa Vargas, Pamela, additional, Olate Mellado, Paola, additional, Yola Gassant, Pascale, additional, Diaz Romero, Paulina, additional, De Santis, Raffaella, additional, Kebudi, Rejin, additional, Boranbayeva, Riza, additional, Vasquez, Roberto, additional, Segura, Romel A., additional, Rosado, Roy Enrique, additional, Gómez, Sandra, additional, Raimbault, Sandra, additional, Gunasekera, Sanjeeva, additional, Makkeyah, Sara M, additional, Buyukkapu Bay, Sema, additional, M Gómez, Sergio, additional, Bouttefroy, Séverine, additional, Islam, Shahnoor, additional, Abouelnaga, Sherif, additional, Torres, Silvio Fabio, additional, Cesaro, Simone, additional, Nunes, Sofia, additional, Rouxinol, Soraia, additional, Bhaumik, Sucharita, additional, Saliyeva, Symbat, additional, Inostroza, Tamara, additional, Velasquez, Thelma, additional, Hnin, Tint Myo, additional, Norén-Nyström, Ulrika, additional, Baretta, Valentina, additional, Jimenez-Antolinez, Yajaira Valentine, additional, Pérez Alonso, Vanesa, additional, Ayer Miller, Vanessa, additional, Gandemer, Virginie, additional, Lotero, Viviana, additional, Mishkova, Volha, additional, Gómez-García, Wendy, additional, Margaryan, Yeva, additional, and Syed, Yumna, additional
- Published
- 2021
- Full Text
- View/download PDF
14. Clima organizacional y alineamiento estratégico del personal médico y asistencial en un Centro de Salud de Guayaquil, 2021
- Author
-
Villamar Palma, Julia Irene and Luque Ramos, Carlos Alberto
- Subjects
Clima organizacional ,Servicio de salud ,Centros de salud - Perú ,purl.org/pe-repo/ocde/ford#3.03.02 [http] - Abstract
La investigación realizada tiene como objetivo determinar la correlación entre el clima organizacional en el alineamiento estratégico del personal médico y asistencial en un Centro de Salud de Guayaquil, 2021. Es una investigación aplicada donde se usó un diseño no experimental descriptivo correlacional. La población de estudio abarco 70 trabajadores de un Centro de Salud de Guayaquil, con una muestra de 50 informantes como resultado de criterios de selección. Durante la toma de datos se elaboró un cuestionario sobre clima organizacional y un cuestionario sobre alineamiento estratégico del personal médico y asistencial conformado de 20 preguntas cada uno. Para el procesamiento de datos se uso la estadística descriptiva, la presentación de resultados se realizó en tablas; para la comprobación de hipótesis se uso la estadística inferencial. Del procesamiento de datos los resultados determinaron un coeficiente de correlación de Pearson de r=0,939 que indica la existencia de correlación del clima organizacional en el alineamiento estratégico del personal médico y asistencial en un Centro de Salud de Guayaquil, 2021, es decir que se cumple, con un buen clima organizacional y además le corresponde un óptimo alineamiento estratégico del personal médico y asistencial, y viceversa. Piura Escuela de Posgrado Dirección de los Servicios de Salud
- Published
- 2021
15. Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study
- Author
-
Buechner, Jochen, Poetschger, Ulrike, Kurzmann, Paulina, Bader, Peter, Dalle, Jean-Hugues, Yesilipek, Akif, Pichler, Herbert, Palma, Julia, Staciuk, Raquel, Sedlacek, Petr, Krivan, Gergely, Ifversen, Marianne, Güngör, Tayfun, Kitra Rousou, Vassiliki, Kalwak, Krzysztof, Toporski, Jacek, Shaw, Peter J., Renard, Marleen, Díaz De Heredia, Cristina, Matic, Toni, Bierings, Marc, Svec, Peter, Meisel, Roland, Balduzzi, Adriana, Locatelli, Franco, Peters, Christina, and Stein, Jerry
- Published
- 2023
- Full Text
- View/download PDF
16. Donación dirigida de sangre de Cordón Umbilical de Hermano Compatible en el Sistema de Salud Público de Chile
- Author
-
Sotomayor, Cristián, Salas, Lucía, Lattus, José, Anguita-Compagnon, Alfonso T., Abarzúa, Carolina, Catalán, Paula, and Palma, Julia
- Subjects
Trasplante de Sangre de Cordón umbilical ,Directed Tissue Donation ,Cord Blood ,Sangre de Cordón ,Hematopoietic Stem Cell Transplantation ,Cord Blood Stem Cell Transplantation ,Trasplante de células progenitoras hematopoyéticas ,Donación dirigida - Abstract
Resumen: Introducción: La sangre de cordón umbilical (SCU) como fuente para trasplante de células proge- nitoras hematopoyéticas (TPH) está bien establecida. Internacionalmente, menos del 10% de los TPH de SCU corresponde a donantes hermanos compatibles. Dentro de la red del Programa Infantil Nacional de Drogas Antineoplásicas (PINDA), existe desde enero 2004 un programa de donación dirigida de SCU para TPH. Pacientes y Método: Se diseñó un estudio observacional, retrospectivo, descriptivo, se revisaron el número y características de las unidades de SCU recolectadas en el PINDA y el número, características y evolución de los pacientes trasplantados con esas unidades entre enero de 2004 y octubre de 2018. Resultados: Sesenta unidades de SCU han sido recolectadas, de ellas 55 con registro completo. La mediana de volumen de las unidades almacenadas fue 74,8 ml (30,0-170,8), la mediana de células nucleadas totales 7,6 x 10e8 (2,0-21,1), mediana de células CD34+ 1,6 x 10e6 (0,2-11,6). Cuatro pacientes con leucemias de alto riesgo fueron trasplantados; mediana de segui miento es de 8 años. Todos desarrollaron complicaciones severas post TPH, uno de ellos falleció de recaída y los tres actualmente vivos presentan un Karnofsky/Lansky 100%. Conclusión: El programa ha permitido el trasplante de 4 pacientes que de otro modo no habrían tenido acceso a un donante. Este programa de donación dirigida puede ser considerado una primera etapa para el desarrollo de un banco público de sangre de cordón umbilical en Chile. Abstract: Introduction: Cord blood (CB) as a source of Hematopoietic Stem Cells for Transplantation (HSCT) is well established. Worldwide, nonetheless, less than 10% of the CB HSCTs are performed with a match sibling donor. Since 2004, the Chilean National Childhood Cancer Program (PINDA) net work, has established a CB directed donation program for HSCT. Patients and Method: An obser vational, descriptive and retrospective study was designed to assess the number and characteristics of the CB units collected in the program as well as the number, clinical characteristics and follow-up of the patients who received an HSCT from those CB units between January 2004 and October 2018. Results: Sixty CB units have been collected; 55 of them with full records and stored. The median volume collected was 74.8 ml (30.0-170.8), the median number of total nucleated cells was 7.6 x 10e8 (2.0-21.1), and the median of CD34+ cells was 1.6 x 10e6 (0.2-11.6). Four high-risk leukemia patients received HSCT, all of them developed severe complications after transplantation and one patient died due to relapse. Those patients currently alive have a 100% Karnofsky/Lansky score. The median follow-up time was 8 years. Conclusion: The PINDA program has allowed 4 patients to be transplan ted who otherwise would not have had access to a donor. This directed donation program could be seen as a model for the development of a public cord blood bank in Chile.
- Published
- 2020
17. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
- Author
-
Burkhardt, B, Taj, M, Garnier, N, Minard-Colin, V, Hazar, V, Mellgren, K, Osumi, T, Fedorova, A, Myakova, N, Verdu-Amoros, J, Andres, M, Kabickova, E, Attarbaschi, A, Chiang, A, Bubanska, E, Donska, S, Hjalgrim, L, Wachowiak, J, Pieczonka, A, Uyttebroeck, A, Lazic, J, Loeffen, J, Buechner, J, Niggli, F, Csoka, M, Krivan, G, Palma, J, Burke, G, Beishuizen, A, Koeppen, K, Mueller, S, Herbrueggen, H, Woessmann, W, Zimmermann, M, Balduzzi, A, Pillon, M, Burkhardt, Birgit, Taj, Mary, Garnier, Nathalie, Minard-Colin, Veronique, Hazar, Volkan, Mellgren, Karin, Osumi, Tomoo, Fedorova, Alina, Myakova, Natalia, Verdu-Amoros, Jaime, Andres, Mara, Kabickova, Edita, Attarbaschi, Andishe, Chiang, Alan Kwok Shing, Bubanska, Eva, Donska, Svetlana, Hjalgrim, Lisa Lyngsie, Wachowiak, Jacek, Pieczonka, Anna, Uyttebroeck, Anne, Lazic, Jelena, Loeffen, Jan, Buechner, Jochen, Niggli, Felix, Csoka, Monika, Krivan, Gergely, Palma, Julia, Burke, G A Amos, Beishuizen, Auke, Koeppen, Kristin, Mueller, Stephanie, Herbrueggen, Heidi, Woessmann, Wilhelm, Zimmermann, Martin, Balduzzi, Adriana, Pillon, Marta, Burkhardt, B, Taj, M, Garnier, N, Minard-Colin, V, Hazar, V, Mellgren, K, Osumi, T, Fedorova, A, Myakova, N, Verdu-Amoros, J, Andres, M, Kabickova, E, Attarbaschi, A, Chiang, A, Bubanska, E, Donska, S, Hjalgrim, L, Wachowiak, J, Pieczonka, A, Uyttebroeck, A, Lazic, J, Loeffen, J, Buechner, J, Niggli, F, Csoka, M, Krivan, G, Palma, J, Burke, G, Beishuizen, A, Koeppen, K, Mueller, S, Herbrueggen, H, Woessmann, W, Zimmermann, M, Balduzzi, A, Pillon, M, Burkhardt, Birgit, Taj, Mary, Garnier, Nathalie, Minard-Colin, Veronique, Hazar, Volkan, Mellgren, Karin, Osumi, Tomoo, Fedorova, Alina, Myakova, Natalia, Verdu-Amoros, Jaime, Andres, Mara, Kabickova, Edita, Attarbaschi, Andishe, Chiang, Alan Kwok Shing, Bubanska, Eva, Donska, Svetlana, Hjalgrim, Lisa Lyngsie, Wachowiak, Jacek, Pieczonka, Anna, Uyttebroeck, Anne, Lazic, Jelena, Loeffen, Jan, Buechner, Jochen, Niggli, Felix, Csoka, Monika, Krivan, Gergely, Palma, Julia, Burke, G A Amos, Beishuizen, Auke, Koeppen, Kristin, Mueller, Stephanie, Herbrueggen, Heidi, Woessmann, Wilhelm, Zimmermann, Martin, Balduzzi, Adriana, and Pillon, Marta
- Abstract
Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.
- Published
- 2021
18. Hematopoietic Stem Cell Transplant
- Author
-
Palma, Julia, primary and Sotomayor, Cristián, additional
- Published
- 2013
- Full Text
- View/download PDF
19. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
- Author
-
Burkhardt, Birgit, primary, Taj, Mary, additional, Garnier, Nathalie, additional, Minard-Colin, Veronique, additional, Hazar, Volkan, additional, Mellgren, Karin, additional, Osumi, Tomoo, additional, Fedorova, Alina, additional, Myakova, Natalia, additional, Verdu-Amoros, Jaime, additional, Andres, Mara, additional, Kabickova, Edita, additional, Attarbaschi, Andishe, additional, Chiang, Alan Kwok Shing, additional, Bubanska, Eva, additional, Donska, Svetlana, additional, Hjalgrim, Lisa Lyngsie, additional, Wachowiak, Jacek, additional, Pieczonka, Anna, additional, Uyttebroeck, Anne, additional, Lazic, Jelena, additional, Loeffen, Jan, additional, Buechner, Jochen, additional, Niggli, Felix, additional, Csoka, Monika, additional, Krivan, Gergely, additional, Palma, Julia, additional, Burke, G. A. Amos, additional, Beishuizen, Auke, additional, Koeppen, Kristin, additional, Mueller, Stephanie, additional, Herbrueggen, Heidi, additional, Woessmann, Wilhelm, additional, Zimmermann, Martin, additional, Balduzzi, Adriana, additional, and Pillon, Marta, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Haploidentical stem cell transplantation for children with high-risk leukemia
- Author
-
Palma, Julia, Salas, Lucia, Carrión, Flavio, Sotomayor, Cristián, Catalán, Paula, Paris, Claudia, Turner, Victoria, Jorquera, Hugo, Handgretinger, Rupert, and Rivera, Gastón K
- Published
- 2012
- Full Text
- View/download PDF
21. Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents
- Author
-
Paris, Claudia, Yates, Lorena, Lama, Pamela, Zepeda, Ana J., Gutiérrez, Daniela, and Palma, Julia
- Published
- 2012
- Full Text
- View/download PDF
22. Cytomegalovirus Infection in Children Undergoing Hematopoietic Stem Cell Transplantation in Chile
- Author
-
Paris, Claudia, Kopp, Katherine, King, Alejandra, Santolaya, Maria E., Zepeda, Ana J., and Palma, Julia
- Published
- 2009
- Full Text
- View/download PDF
23. Establishment of a pediatric HSCT program in a public hospital in Chile
- Author
-
Palma, Julia, Mosso, Claudio, Paris, Claudia, Campbell, Myriam, Tong, Xin, King, Alejandra, Carrion, Flavio, and Rivera, Gaston K.
- Published
- 2006
- Full Text
- View/download PDF
24. 444 - Sharing Best Practice: Establishing a National Vietnamese Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy Consortium
- Author
-
Nguyen, Sang M., Huynh, Phu D.V., Abramovitz, Linda, Agrawal, Anu, Assanasen, Chatchawin, Blair, Sally, Chu, Minh H., Faulkner, Lawrence, Hoang, Tram T.A., Ho, Hang T.K., Horn, Biljana, Huynh, Chau T.B., Le, Anh H., Le, Phuong B., Le, Son T., Noonan, Nancy, Nguyen, Dinh V., Nguyen, Hang T.T., Nguyen, Hoa T.K., Nguyen, Nam H., Nguyen, Nhai T., Nguyen, Tho T., Oh, Jess, Palma, Julia, Phan, Trang T.T., Pham, Anh T.N., Pham, Tuan M., Rees, Hannah, Tan, Poh-Lin, Tran, My, Vo, Binh T.T., Watanabe, Kazuyo, Yi, Hyeon Gyu, Bui, Lan N., and Hermiston, Michelle
- Published
- 2022
- Full Text
- View/download PDF
25. Evaluación de la indicación, consumo y costos de antifúngicos en un hospital pediátrico de Chile
- Author
-
Barraza, Marlon, Barnafi, Natalia, Ortiz, Guillermo, Torres, Juan Pablo, Coria, Paulina, Catalán, Paula, Palma, Julia, and Morales, Jorge
- Subjects
economic impact ,antifungal stewardship ,invasive fungal diseases ,antifúngicos ,Enfermedad fúngica invasora ,Antifungal drugs ,impacto económico - Abstract
Resumen Introducción: El incremento de la enfermedad fúngica invasora (EFI) en pacientes inmunocomprometidos ha conducido a la frecuente prescripción de fármacos altamente activos pero de elevado costo económico. Objetivo: Caracterizar el uso de antifúngicos, evaluar su indicación y determinar consumo y costos asociados. Métodos: Estudio descriptivo, retrospectivo, desde enero de 2015 a abril de 2016. Auditoría de prescripciones y revisión de fichas clínicas; cada prescripción se clasificó de acuerdo a si correspondía a una EFI posible, probable o probada. Se calcularon consumos y costos de tratamientos. Resultados: Se auditaron 152 prescripciones de antifúngicos en 79 pacientes. El costo total de los medicamentos antifúngicos fue de US$ 714.413. El 52,1% del gasto (US $ 372.319) correspondió a indicaciones en EFI probada, 10,7% (US $ 76.377) EFI probable, 0.8% (US $ 5.638) no-EFI, 12,2% (US $ 87.459) EFI posibles y 1,5% (US $ 10.896) EFI descartada y 22,6% (US$ 161.723) fue profilaxis. El mayor consumo fue en indicaciones relacionadas a EFI probada con un DOT probada de 10,54 días, siendo anfotericina B liposomal y voriconazol iv los fármacos con mayor consumo con un DOTprobada AnBL de 3,15 y DOT probada voriconazol iv de 3,01. Conclusiones: El consumo de medicamentos antifúngicos genera altos costos correspondiente al 12% del presupuesto total de farmacia de nuestra institución. El gasto se asoció principalmente a indicaciones en EFI probadas, voriconazol y anfotericina B liposomal los con mayor consumo, lo que sumado a su alto costo y días prolongados de terapia generan un gran impacto en el presupuesto. Background: The increase of invasive fungal disease (IFD) in immunocompromised patients has led to the frequent prescription of highly active antifungal drugs but with a high economic cost. Aim: To characterize the use of antifungals drugs, evaluate its prescription and determine consumption and associated costs. Methods: Retrospective descriptive study from January 2015 to April 2016. Audit of prescriptions and review of clinical files. Each prescription was classified according to whether it corresponded to a possible, probable or proven invasive fungal disease (IFD). Consumptions and treatment costs were calculated. Results: 152 antifungal prescriptions were audited in 79 patients. The total cost of antifungal medications was US $ 714,413. 52.1% of the expenditure (US $ 372,319) corresponded to indications in proven IFD, 10.7% (US $ 76,377) probable IFD, 0.8% (US $ 5,638) non-IFI, 12.2% (US $ 87,459) IFD possible and 1.5% (US $ 10,896) non-IFD and 22.6% (US $ 161,723) was prophylaxis. The highest consumption was in indications related to IFD tested with a proven DOT of 10.54 days, with liposomal amphotericin B and iv voriconazole the drugs with the highest consumption with a DOT probable_AnBL of 3.15 and DOT proven voriconazole iv of 3.01. Conclusions: The consumption of antifungal drug medications generates high costs at 12% of the total pharmacy budget of our institution. The expense was associated mainly with the indications in IFI tested the voriconazole and amphotericin B liposomal with the highest consumption which added to its high cost and prolonged days of general therapy a big impact in the budget.
- Published
- 2018
26. Farmacocinética de posaconazol en la profilaxis y tratamiento de la infección fúngica invasora en niños inmunocomprometidos en un hospital pediátrico
- Author
-
Valenzuela, Romina, García, Patricio, Barraza, Marlon, Palma, Julia, Catalán, Paula, Santolaya, M. Elena, Torres, J. Pablo, and Morales, Jorge
- Subjects
concentraciones plasmáticas ,children ,therapeutic drug monitoring ,Posaconazol ,immunocompromised patients ,monitorización terapéutica de fármacos ,Posaconazole ,niños ,pacientes inmunocomprometidos ,drug levels - Abstract
Resumen Introducción En pediatría no existe consenso en la dosificación de posaconazol (PSC) para profilaxis y tratamiento de la infección fúngica invasora (IFI), usándose la medición de concentraciones plasmáticas (CPs) del fármaco. Objetivo Describir la experiencia de monitoreo de las CPs de PSC en niños inmunocomprometidos con IFI y determinar si las dosis recomendadas alcanzan CPs efectivas en profilaxis (≥ 0,7 µg/mL) y tratamiento (≥ 1,25 µg/mL). Método Análisis retrospectivo en niños que recibieron PSC suspensión como profilaxis o tratamiento entre enero de 2012 y octubre de 2016, en las unidades de Oncología y Trasplante de Médula Ósea del Hospital Calvo Mackenna. Resultados 78 CPs en seis pacientes (4 indicaciones de profilaxis y 4 tratamientos) fueron revisados. La mediana de dosis de PSC fue de 12,5 y 18,8 mg/kg/d para profilaxis y tratamiento, respectivamente, resultando CP mediana de 0,97 y 1,8 μg/mL, respectivamente. En profilaxis, se registraron 40/67 (60%) con CP ≥ 0,70 μg/mL recibiendo una mediana de dosis de 12,5 mg/kg/d. Mientras que para el tratamiento: 5/11 (46%), presentaron CP ≥ 1,25 μg/mL, recibiendo una mediana de dosis de 18 mg/kg/d. Conclusión Nuestros resultados se ajustan a lo recomendado para la dosificación de PSC, pero evidencian una necesidad de realizar una monitorización individualizada para mantener adecuadas CPs. Background There is no consensus on the optimal dosage use of posaconazole (PSC) for invasive fungal infection (IFI) in pediatric patients and normally it is adjusted with drug levels (DLs) ≥ 0.7 μg/ml and ≥ 1.25 μg/ml for prophylaxis and treatment, respectively. Objective To describe the experience of monitoring DLs of PSC in immunocompromised pediatric patients with IFI and to determine if the recommended doses reach CP effective in prophylaxis (≥ 0.7 μg/mL) and treatment (≥ 1.25 μg/mL). Method A retrospective analysis in children who received PSC from January 2012 to October 2016, in the Oncology and Bone Marrow Transplant units at Hospital Calvo Mackenna was done Six patients with 78 DLs were reviewed (4 prophylaxis and 4 treatment). Median PSC dose was 12.5 and 18.8 mg/kg/d for prophylaxis and treatment, resulting in mean DLs of 0.97 and 1.8 μg/mL respectively. In prophylaxis 40/67 (60%) were recorded with DLs ≥ 0.70 μg/mL receiving a median dose of 12.5 mg/kg/d. While for treatment: 5/11 (46%) presented DLs ≥ 1.25 μg/mL, receiving a median dose of 18 mg/kg/d. Conclusion Our results are in line with the recommended for PSC dosage, but individualized monitoring is required to maintain adequate DLs.
- Published
- 2018
27. Evaluación de la indicación, consumo y costos de antifúngicos en un hospital pediátrico de Chile
- Author
-
Barraza, Marlon, primary, Barnafi, Natalia, additional, Ortiz, Guillermo, additional, Torres, Juan Pablo, additional, Coria, Paulina, additional, Catalán, Paula, additional, Palma, Julia, additional, and Morales, Jorge, additional
- Published
- 2018
- Full Text
- View/download PDF
28. Evaluación de interacción medicamentosa de voriconazol-ciclosporina en pacientes pediátricos que reciben trasplante de precursores hematopoyéticos (2013-2014)
- Author
-
Valenzuela, Romina, Torres, Juan P, Salas, Carolina, Gajardo, Iván, Palma, Julia, Catalán, Paula, Santolaya, M. Elena, and Morales, Jorge
- Subjects
level of cyclosporine ,trasplante de progenitores hematopoyéticos ,concentraciones plasmáticas de ciclosporina ,hematopoietic stem cell transplantation (HSCT) ,Interacción medicamentosa ,Drug interactions - Abstract
Introducción: Las interacciones medicamentosas (IM) en el trasplante de progenitores hematopoyéticos (TPH) son comunes y clínicamente significativas, especialmente en: anticonvulsivantes, voriconazol (VCZ) y ciclosporina (CsA). Objetivo: Describir las interacciones de CsA-VCZ en pacientes con TPH. Métodos: Estudio descriptivo, retrospectivo, en pacientes receptores de TPH entre enero de 2013 y diciembre de 2014 en la Unidad de Trasplante de Médula Ósea del Hospital Dr. Luis Calvo Mackenna, que recibieran CsA y VCZ. Resultados: Edad media: 5 años (3-6), peso promedio: 20 kg (17-30). Se analizaron 63 concentraciones plasmáticas de CsA, 27 eran concentraciones de CsA previas al uso de VCZ y 36 concentraciones plasmáticas de CsA concomitantes con VCZ. En el grupo de CsA previo a VCZ, la dosis de CsA fue 4,6 ± 2,6 (mg/kg/día) y la concentración media de CsA 188,8 ± 84,1 (μg/ml). En el grupo de CsA en forma concomitante con VCZ, la dosis de CsA fue de 5,5 ± 3,0 (mg/kg/día) (p 0,07) y la concentración media de CsA fue: 232,5 ± 106,7 (μg/ml) (p = 0,04). Conclusión: Se demostró un aumento de las concentraciones plasmáticas de CsA en IM con VCZ. La monitorización terapéutica podría mejorar el manejo de la IM y optimizar la coadministración de CsA y VCZ. Background: Drug interactions (DI) in patients receiving hematopoietic stem cell transplantation (HSCT) are common and clinically significant, highlighting: anticonvulsants, voriconazole (VCZ) and cyclosporine (CsA), which require monitoring. Objective: To describe the interactions between CsA-VCZ in children undergoing HSCT. Methods: Retrospective, descriptive study in immunocompromised children hospitalized since January 2013 to December 2014 at Bone Marrow Transplant Unit, Hospital Dr. Luis Calvo Mackenna, who received CsA and VCZ. Results: The median age was 5 years (3-6) and the median weight was 20 kg (17-30). Sixtythree baseline drug levels were analyzed, of those, 27 were CsA drug levels obtained previous to using VCZ and 36 were CsA drug levels collected concomitantly with VCZ. In the group CsA previous to VCZ, the CsA dose was 4.6 ± 2.6 (mg/ kg/ day) and the CsA average level was 188.8 ± 84.1 (μg/ml). In the group of CsA concomitantly with VCZ, the dose of CsA was 5.5 ± 3.0 (mg/ kg/day) (p = 0.07) and CsA average level was significantly higher: 232.5 ± 106.7 (μg/ml) (p = 0.04). Conclusion: This study shows an increased level of CsA when it is used together with VCZ. Therapeutic drug monitoring could improve the management of the DI and optimize the co-administration of CsA and VCZ.
- Published
- 2017
29. Farmacocinética de posaconazol en la profilaxis y tratamiento de la infección fúngica invasora en niños inmunocomprometidos en un hospital pediátrico
- Author
-
Valenzuela, Romina, primary, García, Patricio, additional, Barraza, Marlon, additional, Palma, Julia, additional, Catalán, Paula, additional, Santolaya, M. Elena, additional, Torres, J. Pablo, additional, and Morales, Jorge, additional
- Published
- 2018
- Full Text
- View/download PDF
30. Propuesta de estrategias de marketing para fortalecer la atención al cliente en Gruvalcorp S.A
- Author
-
Villavicencio Palma, Julia del Carmen and Alvarado Márquez, Mariana De Jesús
- Subjects
PROPUESTA ,ATENCION AL CLIENTE ,COMPLACIENCIA ,ESTRATEGIAS ,CALIDAD ,MARKETING ,FORTALECER - Abstract
Para que una empresa logre sus objetivos debe diseñar planes estratégicos a corto, mediano o largo plazo, dependiendo la actividad y magnitud del negocio. El presente estudio fue elaborado en la empresa Gruvalcorp S.A. en el sur de la ciudad de Guayaquil, cuyo objetivo es desarrollar métodos estratégicos que permitan potenciar la atención al cliente, con la finalidad de sea implementado cuando se requiera, a fin de optimizar y alinear los procesos de marketing en Gruvalcorp SA. , mediante un análisis general para conocer la situación actual de la empresa y de ésta forma definir parámetros para el desarrollo de propuestas, la metodología empleada se encuentra basada en un estudio de campo realizado con evaluaciones a los clientes y al personal que labora para identificar factores, es necesario recalcar que los clientes a su vez realizan evaluaciones visuales con la finalidad de identificar la experiencia en la atención. Establecida la situación actual de la empresa, se ha procedido al desarrollo de las Propuestas Estratégicas de Marketing, es necesario mencionar que los clientes no solo se fijan en marcas, sino también por el trato que se le brinda al cliente. Una vez obtenido los resultados, se concluye que inmerso en el presente estudio resaltan situaciones en las que causas de complacencia de las marcas que sobresalen en el mercado son equivalentes, y que la atención que brinda el personal de ventas es muy importante ya que es considerado como la imagen en la empresa y la calidad de atención debe ser representativa. or a company to achieve its objectives must devise strategic plans to short, medium or long term, depending on the activity and size of deal. This study was prepared in the company Gruvalcorp S.A. in the south of the city of Guayaquil, whose aim is to develop strategic methods to enhance the customer service, in order to be implemented when required, to optimize and align marketing processes in Gruvalcorp SA., through a general analysis was conducted to know the current situation of the company and thus define the parameters to be used in the development of the proposals, the methodology is based on a field study conducted to customers, the object of study and to staff working to identify factors, it is necessary to stress that customers make the same assessments visual in order to identify the care experience. Established the current status of company, has carried out the development of strategic marketing proposals, it is necessary to mention that customers do not just look at brands, but also for the treatment that is offered to client. After obtaining the results, it is concluded that immersed in this study highlight situations where the causes of complacency brands that stand out in the market are equivalent with regard to the care provided by the sales staff, it is noteworthy that the seller role is very important because it is considered as the picture on the company and the quality of care must be representative.
- Published
- 2016
31. Evaluación de interacción medicamentosa de voriconazol-ciclosporina en pacientes pediátricos que reciben trasplante de precursores hematopoyéticos (2013-2014)
- Author
-
Valenzuela, Romina, primary, Torres, Juan P, additional, Salas, Carolina, additional, Gajardo, Iván, additional, Palma, Julia, additional, Catalán, Paula, additional, Santolaya, M. Elena, additional, and Morales, Jorge, additional
- Published
- 2017
- Full Text
- View/download PDF
32. Infección por Mycobacterium tuberculosis en una niña sometida a trasplante de progenitores hematopoyéticos
- Author
-
Palma, Julia, Catalán, Paula, Mardones, Patricia, and Santolaya, M. Elena
- Subjects
liver nodules ,nódulos hepáticos ,HSCT ,TPH ,biopsia ,biopsy ,Mycobacterium tuberculosis - Abstract
Se presenta el caso clínico de una niña de 10 años, con una leucemia linfoblástica aguda en recaída, sometida a un trasplante de progenitores hematopoyéticos (TPH) haploidéntico, con enfermedad injerto contra hospedero cutánea y digestiva grado II, en tratamiento con corti-costeroides y ciclosporina, que presentó el día +54 posttrasplante fiebre y compromiso de estado general. Dentro del estudio de su cuadro febril se practicaron imágenes que mostraron presencia de nódulos pulmonares y hepáticos. Se realizó una biopsia hepática cuyo estudio incluyó histología, tinciones y cultivo para bacterias y hongos. La tinción de Ziehl Nielsen de tejido hepático, así como las baciloscopias de contenido gástrico, aspirado traqueal y de fluido bronquial obtenido por lavado broncoalveolar (LBA) fueron positivas. El informe definitivo de cultivo confirmó Mycobacterium tuberculosis en contenido gástrico, esputo, LBA y tejido hepático, sensible a rifampicina, isoniazida, estreptomicina y etambutol, con determinación de mutaciones de genes rpoβ y kat G (-). Se confirmó el diagnóstico de tuberculosis, por lo que recibió tratamiento diario con cuatro fármacos por dos meses y luego terapia trisemanal con rifampicina, isoniazida y etambutol por nueve meses. Controlada por los equipos de trasplante, infectología y broncopulmonar, la paciente se mantiene actualmente en buenas condiciones generales, con imágenes con resolución del compromiso hepático y pulmonar y baciloscopias negativas. La infección por M. tuberculosis debe formar parte del diagnóstico diferencial de los cuadros febriles en los pacientes sometidos a TPH, y la toma de biopsia debe ser una práctica habitual y precoz en el enfrentamiento diagnóstico de estos pacientes. We report the case of a 10 year old girl with a relapsed acute lymphoblastic leukemia, who underwent a haploidentical hematopoietic stem cell transplant (HSCT), with grade II skin and digestive graft versus host disease, treated with corticosteroids and cyclosporine. On day + 54, she presented fever, with no other remarkable clinical findings. Imaging study showed the presence of lung and liver nodules, liver biopsy was performed. The study included histology, staining and culture for bacteria and fungi, and the preservation of a piece of tissue at -20°C for future prospective studies. Ziehl Nielsen stain was positive, and study for Mycobacterium infection was performed. Microbiological smears of tracheal and gastric aspirate, and bronchial fluid obtained by bronchoalveolar lavage (BAL) were positive. The final report confirmed Mycobacterium tuberculosis in gastric content, sputum, BAL and liver tissue, susceptible to rifampin, isoniazid, streptomycin and ethambutol, with determination of mutations for genes rpoβ and kat G (-). Tuberculosis (TB) diagnosis was confirmed. The girl received daily therapy for two months and then she continued on three times per week therapy for 9 months. Controlled by the transplant, infectious diseases and respiratory teams, the patient remained in good general condition, with radiologic resolution of pulmonary and liver involvement and negative smears. We conclude that Mycobacterium tuberculosis infection should be part of differential diagnosis of febrile illness in patients undergoing HSCT, and biopsy should be a standard practice of early diagnosis in these patients.
- Published
- 2013
33. Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts
- Author
-
Rolon, Juliana Martinez, primary, Baldomero, Helen, additional, Jaimovich, Gregorio, additional, Rivas, Maria, additional, Bouzas, Luis Fernando, additional, Bonfim, Carmem Maria Sales, additional, Palma, Julia, additional, Karduss-Urueta, Amado, additional, Ubidia, Diana, additional, Bujan-Boza, Willem, additional, Gonzalez-Ramella, Oscar, additional, Ruiz-Arguelles, Guillermo J., additional, Gomez-Almaguer, David, additional, Espino, German A., additional, Fanilla, Ernesto, additional, Gonzalez, Derlis, additional, Carrasco, Antonio, additional, Galeano, Sebastian, additional, Borelli, Walter Gabriel, additional, Gimenez, Marcos Hernandez, additional, Pasquini, Marcelo C., additional, Kodera, Yoshihisa, additional, Niederwieser, Dietger, additional, and Seber, Adriana, additional
- Published
- 2015
- Full Text
- View/download PDF
34. Proteína C reactiva y procalcitonina como marcadores de infección bacteriana en niños con neutropenia febril posterior a trasplante alogénico de progenitores hematopoyéticos
- Author
-
Schmidt, Nadia, Palma, Julia, King, Alejandra, and Santolaya, María Elena
- Subjects
Bacterial infections ,C-Reactive protein ,Hematopoietic stem cells - Abstract
Background: The main causes of complications of allogenic hematopoietic stem cell transplantation are infections and graft versus host disease. Aim: To assess the predictive value of C reactive protein (CRP) and procalcitonin (PCT) in the diagnosis of invasive bacterial infections in children with febrüe neutropenia after an allogenic hematopoietic stem cell transplantation. Material and methods: Prospective follow up of patients aged 18 years or ¡ess, with febrile neutropenia after an allogenic hematopoietic stem cell transplantation. In all patients, cultures from sterile sites, CRP and PCT determinations were done. CRP levels were also measured prior to transplantation and three times per week for 30 days after the procedure. An independent evaluator, blinded to the results of CRP and PCT, classified children as with or without invasive bacterial infection. Results: Thirty three patients aged 9±5 years (21 males) were studied. Eight had an invasive bacterial infection. Sensitivity, specificity, positive and negative predictive values of a CRP ³90 mg/L for the diagnosis of invasive bacterial infection were 25, 80, 29 and 77%, respectively. The figures for a PCT ³0.7 ng/ml were 43, 78, 38 and 82%, respectively. No differences in repeated CRP values measured during evolution, were observed. Conclusions: A CRP ³90 mg/L or a PCT ³0.7 ng/ml had a high specificity and negative predictive value but low sensitivity for the diagnosis of invasive bacterial infections in recipients of allogenic hematopoietic stem cell transplantation (Rev Méd Chile 2007; 135: 982-89)
- Published
- 2007
35. Currículum y democracia : por un cambio en la cultura popular
- Author
-
Cortés Palma, Julia
- Subjects
pedagogía diferencial ,desarrollo de programas de estudios ,pluralismo cultural - Abstract
Comunicación en la que se exponen las características que debe cumplir la escuela y el curriculum para adecuarse a la diversidad cultural de los alumnos que acogen las instituciones escolares. Extremadura ESP
- Published
- 2002
36. Infección por Mycobacterium tuberculosis en una niña sometida a trasplante de progenitores hematopoyéticos
- Author
-
Palma, Julia, primary, Catalán, Paula, additional, Mardones, Patricia, additional, and Santolaya, M. Elena, additional
- Published
- 2013
- Full Text
- View/download PDF
37. Haploidentical Stem Cell Transplantation for Children with High-Risk Leukemia In Chile: Report of the First 15 Cases.
- Author
-
Palma, Julia I, primary, Salas, Lucia, additional, Carrion, Flavio, additional, Sotomayor, Cristián, additional, Catalán, Paula, additional, Handgretinger, Rupert, additional, and Rivera, Gaston, additional
- Published
- 2010
- Full Text
- View/download PDF
38. Proteína C reactiva y procalcitonina como marcadores de infección bacteriana en niños con neutropenia febril posterior a trasplante alogénico de progenitores hematopoyéticos
- Author
-
Schmidt, Nadia, primary, Palma, Julia, additional, King, Alejandra, additional, and Santolaya, María Elena, additional
- Published
- 2007
- Full Text
- View/download PDF
39. Fundações estatais de direito privado: viabilidade jurídica do PLP n. 92/2007
- Author
-
PALMA, Juliana Bonacorsi de
- Subjects
Fundações Estatais de Direito Privado ,Gestão Contratual ,Organizações Sociais ,Prestação de Serviços de Saúde ,Law ,Law in general. Comparative and uniform law. Jurisprudence ,K1-7720 ,Medical legislation ,K3601-3611 - Abstract
O presente artigo tem por objeto a análise da viabilidade jurídica do Projeto de Lei Complementar n. 92/2007, que se destina a disciplinar as fundações estatais de direito privado. Para tanto, foram identificados os obstáculos jurídicos atinentes ao tema das fundações governamentais a partir do relato do processo legislativo do PLP n. 92/2007, quais sejam, imprecisão semântica do termo "fundação pública", indeterminação do regime jurídico de direito privado e dúvidas quanto à possibilidade de as fundações estatais conferirem eficiência à Administração Pública. Em seguida, cada aspecto foi analisado por meio de estudo doutrinário e normativo. Como resultado da pesquisa, constatou-se que o modelo de fundação estatal proposto pelo referido projeto ainda não é juridicamente viável na medida em que não conseguiu vencer a celeuma terminológica que, consequentemente, impede a identificação mais precisa do regime de direito privado. Quanto à eficiência, concluiu-se que a mera previsão do regime de direito privado não é suficiente para dotar a Administração Pública de flexibilidade de gestão e eficiência, fazendo-se necessária a adoção de instrumentos contratuais.
- Published
- 2009
- Full Text
- View/download PDF
40. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
- Author
-
Burkhardt, Birgit, Taj, Mary, Garnier, Nathalie, Minard-Colin, Veronique, Hazar, Volkan, Mellgren, Karin, Osumi, Tomoo, Fedorova, Alina, Myakova, Natalia, Verdu-Amoros, Jaime, Andres, Mara, Kabickova, Edita, Attarbaschi, Andishe, Chiang, Alan Kwok Shing, Bubanska, Eva, Donska, Svetlana, Hjalgrim, Lisa Lyngsie, Wachowiak, Jacek, Pieczonka, Anna, Uyttebroeck, Anne, Lazic, Jelena, Loeffen, Jan, Buechner, Jochen, Niggli, Felix, Csoka, Monika, Krivan, Gergely, Palma, Julia, Burke, GA Amos, Beishuizen, Auke, Koeppen, Kristin, Mueller, Stephanie, Herbrueggen, Heidi, Woessmann, Wilhelm, Zimmermann, Martin, Balduzzi, Adriana, and Pillon, Marta
- Subjects
children and adolescents ,immune system diseases ,hemic and lymphatic diseases ,stem cell transplant ,refractory and relapsed non-Hodgkin lymphoma ,3. Good health - Abstract
Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.
41. International Society of Paediatric Oncology (SIOP) Global Mapping Programme: Latin American Society of Pediatric Oncology (SLAOP) country-level report.
- Author
-
Cappellano A, Gorostegui M, Gonzalez-Ramella O, Filho NPC, Valencia D, Chantada L, Sampor C, Serrano MJ, Macedo C, Ramirez O, Sardinas S, Lezcano E, Calderón P, Gamboa Y, Fu L, Gómez W, Schelotto M, Ugaz C, Lobos P, Aguiar SDS, Moreno K, Palma J, Sánchez G, Moschella F, Gassant PYH, Velasquez T, Quintero K, Moreno F, Villarroel M, Fuentes Alabi S, Vasquez L, Challinor J, and Chantada GL
- Abstract
Background: Latin American countries are improving childhood cancer care, showing strong commitment to implement the Global Initiative for Childhood Cancer, but there are scant publications of the situation at a continental level., Methods: As part of the International Society of Paediatric Oncology Global Mapping project, delegates of each country participating in the Latin American Society of Pediatric Oncology (SLAOP) and chairs of national pediatric oncology societies and cooperative groups were invited to provide information regarding availability of national pediatric cancer control programs (NPCCP), pediatric oncology laws, pediatric oncology tumor registries, and training programs and support to diagnosis and treatment., Results: Nineteen of the 20 countries participating in SLAOP responded. National delegates reported nine countries with NPCCP and four of them were launched in the past 5 years. National pediatric tumor registries are available in eight countries, and three provided published survival results. Fellowship programs for training pediatric oncologists are available in 12 countries. National delegates reported that eight countries provide support to most essential diagnosis and treatments and 11 provide partial or minimal support that is supplemented by civil society organizations. Seven countries have a pediatric oncology law. There are three international cooperative groups and four national societies for pediatric oncology., Conclusion: Despite many challenges, there were dramatic advances in survivorship, access to treatment, and availability of NPCCP in Latin America. Countries with highest social development scores in general provide more complete support and are more likely to have NPCCP, training programs, and reported survival results., (© 2024 Wiley‐Liss, Inc., A Wiley Company.)
- Published
- 2024
- Full Text
- View/download PDF
42. [Evaluation dosing intravenous voriconazole three times a day vs twice daily for the treatment of invasive aspergillosis in immunocompromised children: therapeutic drugs monitoring and safety].
- Author
-
Barraza M, Torres JP, Coria P, Miranda R, Palma J, García P, Azócar M, Santolaya ME, and Morales J
- Subjects
- Antifungal Agents, Child, Humans, Pharmaceutical Preparations, Voriconazole, Aspergillosis drug therapy, Invasive Fungal Infections
- Abstract
Background: Voriconazole is the antifungal of choice for the treatment of invasive aspergillosis (IA). Plasma concentrations (PCs) > 1 μg / mL llave been associated with better therapeutic results which have not always been achieved during treatment in immunocompromised children. In the necessity to initiate early and effective therapy for the infection, it is relevant to establish the voriconazole administration regimen that is associated with optimal PCs in this population., Aim: To compare the PC and safety of intravenous (IV) voriconazole, dosed BID and TID in immunocompromised children with indication of antifungal treatment., Method: Retrospective observational study since January 2015 until July 2018 in a highly complex pediatric hospital in Santiago of Chile, in patients aged 0 to 17 years who received treatment with IV voriconazole. Those with renal replacement therapy, liver failure and / or renal failure were excluded. Trough PCs were compared between a group with BID dosing regimen versus another group with TID administration. Adverse reactions were evaluated in both groups., Results: 137 trough PCs were obtained in 76 children, with a median age of 9 years (0-17 years) in the BID group and 9 years (0-16) in the TID group with a median weight of 27 kg (6-83 kg) and 28 kg (9.3-60 kg), respectively. Patients < 12 years old exposed to TID dosages are 4.65 times (OR: 4.65, 95% CI 1.93-11.2) more likely to have PC > 1 gg/mL compared to BID administration (p = 0.001). Eight adverse reactions were reported, mainly photophobia, with no significant difference found between the BID and TID groups., Conclusion: TID dosages are associated with a greater probability of obtaining adequate exposure to voriconazole in patients < 12 years old compared to BID dosages, with a low frequency of adverse reactions.
- Published
- 2022
- Full Text
- View/download PDF
43. Directed sibling donor cord blood donation in the Chilean Public Health System.
- Author
-
Sotomayor C, Salas L, Lattus J, Anguita-Compagnon AT, Abarzúa C, Catalán P, and Palma J
- Subjects
- Adolescent, Child, Child, Preschool, Chile, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, National Health Programs, Outcome Assessment, Health Care, Public Health, Retrospective Studies, Blood Donors, Directed Tissue Donation, Fetal Blood, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Siblings
- Abstract
Introduction: Cord blood (CB) as a source of Hematopoietic Stem Cells for Transplantation (HSCT) is well established. Worldwide, nonetheless, less than 10% of the CB HSCTs are performed with a match sibling donor. Since 2004, the Chilean National Childhood Cancer Program (PINDA) net work, has established a CB directed donation program for HSCT., Patients and Method: An obser vational, descriptive and retrospective study was designed to assess the number and characteristics of the CB units collected in the program as well as the number, clinical characteristics and follow-up of the patients who received an HSCT from those CB units between January 2004 and October 2018., Results: Sixty CB units have been collected; 55 of them with full records and stored. The median volume collected was 74.8 ml (30.0-170.8), the median number of total nucleated cells was 7.6 x 10e8 (2.0-21.1), and the median of CD34+ cells was 1.6 x 10e6 (0.2-11.6). Four high-risk leukemia patients received HSCT, all of them developed severe complications after transplantation and one patient died due to relapse. Those patients currently alive have a 100% Karnofsky/Lansky score. The median follow-up time was 8 years., Conclusion: The PINDA program has allowed 4 patients to be transplan ted who otherwise would not have had access to a donor. This directed donation program could be seen as a model for the development of a public cord blood bank in Chile.
- Published
- 2020
- Full Text
- View/download PDF
44. [Evaluation of the prescription, consumption and costs of antifungal drugs in a pediatric hospital in Chile].
- Author
-
Barraza M, Barnafi N, Ortiz G, Torres JP, Coria P, Catalán P, Palma J, and Morales J
- Subjects
- Adolescent, Antifungal Agents classification, Child, Child, Preschool, Chile, Female, Hospitals, Pediatric, Humans, Immunocompromised Host drug effects, Infant, Invasive Fungal Infections classification, Male, Retrospective Studies, Young Adult, Antifungal Agents economics, Antifungal Agents therapeutic use, Drug Costs, Invasive Fungal Infections drug therapy, Invasive Fungal Infections economics
- Abstract
Background: The increase of invasive fungal disease (IFD) in immunocompromised patients has led to the frequent prescription of highly active antifungal drugs but with a high economic cost., Aim: To characterize the use of antifungals drugs, evaluate its prescription and determine consumption and associated costs., Methods: Retrospective descriptive study from January 2015 to April 2016. Audit of prescriptions and review of clinical files. Each prescription was classified according to whether it corresponded to a possible, probable or proven invasive fungal disease (IFD). Consumptions and treatment costs were calculated., Results: 152 antifungal prescriptions were audited in 79 patients. The total cost of antifungal medications was US $ 714,413. 52.1% of the expenditure (US $ 372,319) corresponded to indications in proven IFD, 10.7% (US $ 76,377) probable IFD, 0.8% (US $ 5,638) non-IFI, 12.2% (US $ 87,459) IFD possible and 1.5% (US $ 10,896) non-IFD and 22.6% (US $ 161,723) was prophylaxis. The highest consumption was in indications related to IFD tested with a proven DOT of 10.54 days, with liposomal amphotericin B and iv voriconazole the drugs with the highest consumption with a DOT probable_AnBL of 3.15 and DOT proven voriconazole iv of 3.01., Conclusions: The consumption of antifungal drug medications generates high costs at 12% of the total pharmacy budget of our institution. The expense was associated mainly with the indications in IFI tested the voriconazole and amphotericin B liposomal with the highest consumption which added to its high cost and prolonged days of general therapy a big impact in the budget.
- Published
- 2018
- Full Text
- View/download PDF
45. [Pharmacokinetics of posaconazol in the prophylaxis and treatment of invasive fungal infection in immunocompromised children in a pediatric hospital].
- Author
-
Valenzuela R, García P, Barraza M, Palma J, Catalán P, Santolaya ME, Torres JP, and Morales J
- Subjects
- Adolescent, Antifungal Agents administration & dosage, Antifungal Agents blood, Child, Child, Preschool, Dose-Response Relationship, Drug, Drug Interactions, Drug Monitoring, Female, Hospitals, Pediatric, Humans, Immunocompromised Host drug effects, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Retrospective Studies, Treatment Outcome, Triazoles administration & dosage, Triazoles blood, Antifungal Agents pharmacokinetics, Immunocompetence drug effects, Invasive Fungal Infections drug therapy, Invasive Fungal Infections prevention & control, Triazoles pharmacokinetics
- Abstract
Background There is no consensus on the optimal dosage use of posaconazole (PSC) for invasive fungal infection (IFI) in pediatric patients and normally it is adjusted with drug levels (DLs) ≥ 0.7 μg/ml and ≥ 1.25 μg/ml for prophylaxis and treatment, respectively. Objective To describe the experience of monitoring DLs of PSC in immunocompromised pediatric patients with IFI and to determine if the recommended doses reach CP effective in prophylaxis (≥ 0.7 μg/mL) and treatment (≥ 1.25 μg/mL). Method A retrospective analysis in children who received PSC from January 2012 to October 2016, in the Oncology and Bone Marrow Transplant units at Hospital Calvo Mackenna was done Six patients with 78 DLs were reviewed (4 prophylaxis and 4 treatment). Median PSC dose was 12.5 and 18.8 mg/kg/d for prophylaxis and treatment, resulting in mean DLs of 0.97 and 1.8 μg/mL respectively. In prophylaxis 40/67 (60%) were recorded with DLs ≥ 0.70 μg/mL receiving a median dose of 12.5 mg/kg/d. While for treatment: 5/11 (46%) presented DLs ≥ 1.25 μg/mL, receiving a median dose of 18 mg/kg/d. Conclusion Our results are in line with the recommended for PSC dosage, but individualized monitoring is required to maintain adequate DLs.
- Published
- 2018
- Full Text
- View/download PDF
46. [Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013-2014)].
- Author
-
Valenzuela R, Torres JP, Salas C, Gajardo I, Palma J, Catalán P, Santolaya ME, and Morales J
- Subjects
- Antifungal Agents blood, Child, Child, Preschool, Cyclosporine blood, Drug Interactions, Humans, Immunocompromised Host, Immunosuppressive Agents blood, Male, Retrospective Studies, Time Factors, Voriconazole blood, Antifungal Agents administration & dosage, Cyclosporine administration & dosage, Drug Monitoring, Hematopoietic Stem Cell Transplantation methods, Immunosuppressive Agents administration & dosage, Voriconazole administration & dosage
- Abstract
Background: Drug interactions (DI) in patients receiving hematopoietic stem cell transplantation (HSCT) are common and clinically significant, highlighting: anticonvulsants, voriconazole (VCZ) and cyclosporine (CsA), which require monitoring., Objective: To describe the interactions between CsA-VCZ in children undergoing HSCT., Methods: Retrospective, descriptive study in immunocompromised children hospitalized since January 2013 to December 2014 at Bone Marrow Transplant Unit, Hospital Dr. Luis Calvo Mackenna, who received CsA and VCZ., Results: The median age was 5 years (3-6) and the median weight was 20 kg (17-30). Sixtythree baseline drug levels were analyzed, of those, 27 were CsA drug levels obtained previous to using VCZ and 36 were CsA drug levels collected concomitantly with VCZ. In the group CsA previous to VCZ, the CsA dose was 4.6 ± 2.6 (mg/ kg/ day) and the CsA average level was 188.8 ± 84.1 (μg/ml). In the group of CsA concomitantly with VCZ, the dose of CsA was 5.5 ± 3.0 (mg/ kg/day) (p = 0.07) and CsA average level was significantly higher: 232.5 ± 106.7 (μg/ml) (p = 0.04)., Conclusion: This study shows an increased level of CsA when it is used together with VCZ. Therapeutic drug monitoring could improve the management of the DI and optimize the co-administration of CsA and VCZ.
- Published
- 2017
- Full Text
- View/download PDF
47. [Mycobacterium tuberculosis infection in a pediatric patient who underwent a hematopoietic stem cell transplant].
- Author
-
Palma J, Catalán P, Mardones P, and Santolaya ME
- Subjects
- Child, Female, Humans, Immunocompetence, Precursor Cell Lymphoblastic Leukemia-Lymphoma surgery, Tuberculosis, Pulmonary immunology, Hematopoietic Stem Cell Transplantation adverse effects, Mycobacterium tuberculosis isolation & purification, Tuberculosis, Pulmonary diagnosis
- Abstract
We report the case of a 10 year old girl with a relapsed acute lymphoblastic leukemia, who underwent a haploidentical hematopoietic stem cell transplant (HSCT), with grade II skin and digestive graft versus host disease, treated with corticosteroids and cyclosporine. On day + 54, she presented fever, with no other remarkable clinical findings. Imaging study showed the presence of lung and liver nodules, liver biopsy was performed. The study included histology, staining and culture for bacteria and fungi, and the preservation of a piece of tissue at -20°C for future prospective studies. Ziehl Nielsen stain was positive, and study for Mycobacterium infection was performed. Microbiological smears of tracheal and gastric aspirate, and bronchial fluid obtained by bronchoalveolar lavage (BAL) were positive. The final report confirmed Mycobacterium tuberculosis in gastric content, sputum, BAL and liver tissue, susceptible to rifampin, isoniazid, streptomycin and ethambutol, with determination of mutations for genes rpoβ and kat G (-). Tuberculosis (TB) diagnosis was confirmed. The girl received daily therapy for two months and then she continued on three times per week therapy for 9 months. Controlled by the transplant, infectious diseases and respiratory teams, the patient remained in good general condition, with radiologic resolution of pulmonary and liver involvement and negative smears. We conclude that Mycobacterium tuberculosis infection should be part of differential diagnosis of febrile illness in patients undergoing HSCT, and biopsy should be a standard practice of early diagnosis in these patients.
- Published
- 2013
- Full Text
- View/download PDF
48. [C reactive protein and procalcitonin levels for the diagnosis of invasive bacterial infections in allogenic hematopoietic stem cell transplantation recipients].
- Author
-
Schmidt N, Palma J, King A, and Santolaya ME
- Subjects
- Adolescent, Anti-Infective Agents therapeutic use, Bacterial Infections blood, Bacterial Infections drug therapy, Biomarkers blood, Calcitonin Gene-Related Peptide, Child, Child, Preschool, Female, Fever of Unknown Origin etiology, Humans, Infant, Infant, Newborn, Male, Neutropenia blood, Neutropenia microbiology, Predictive Value of Tests, Prospective Studies, Sepsis blood, Sepsis diagnosis, Shock, Septic blood, Shock, Septic diagnosis, Bacterial Infections diagnosis, C-Reactive Protein analysis, Calcitonin blood, Hematopoietic Stem Cell Transplantation adverse effects, Protein Precursors blood
- Abstract
Background: The main causes of complications of allogenic hematopoietic stem cell transplantation are infections and graft versus host disease., Aim: To assess the predictive value of C reactive protein (CRP) and procalcitonin (PCT) in the diagnosis of invasive bacterial infections in children with febrile neutropenia after an allogenic hematopoietic stem cell transplantation., Material and Methods: Prospective follow up of patients aged 18 years or less, with febrile neutropenia after an allogenic hematopoietic stem cell transplantation. In all patients, cultures from sterile sites, CRP and PCT determinations were done. CRP levels were also measured prior to transplantation and three times per week for 30 days after the procedure. An independent evaluator, blinded to the results of CRP and PCT, classified children as with or without invasive bacterial infection., Results: Thirty three patients aged 9+/-5 years (21 males) were studied. Eight had an invasive bacterial infection. Sensitivity, specificity, positive and negative predictive values of a CRP > or = 90 mg/L for the diagnosis of invasive bacterial infection were 25, 80, 29 and 77%, respectively. The figures for a PCT > or = 0.7 ng/ml were 43, 78, 38 and 82%, respectively. No differences in repeated CRP values measured during evolution, were observed., Conclusions: A CRP > or = 90 mg/L or a PCT > or = 0.7 ng/ml had a high specificity and negative predictive value but low sensitivity for the diagnosis of invasive bacterial infections in recipients of allogenic hematopoietic stem cell transplantation.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.